TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32183793
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual - weekly individual therapy sessions of 30-45 min with a psychotherapist or social worker
Study: 32880104
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT)
Study: 35732620
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/d for 12 weeks
Study: 36228978
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using methylene blue and IPL (560 to 700 nm, fluence 12 J/cm2)
Study: 36228978
Drug: Combined fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined fractional CO2 laser and photodynamic therapy
Study: 32331806
Drug: Two-dose MMR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose MMR vaccination at 9 months and 2.5 years
Study: 35701778
Drug: Ninjin'yoeito (NYT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ninjin'yoeito (NYT) 7.5 g/day along with 100 mg/day iron supplementation
Study: 35701778
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation 100 mg/day
Study: 32467034
Drug: Nebulized N-acetyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized N-acetyl cysteine (NAC), 2 ml of 10% NAC nebulized every six hours.
Study: 36415122
Drug: JNJ-73763989 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 (100 mg)
Study: 36415122
Drug: JNJ-73763989 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 (200 mg)
Study: 36415122
Drug: JNJ-73763989 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-73763989 (100 mg) and (200 mg)
Study: 35656677
Drug: Denosumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (5 mg/0.2 mL)
Study: 35225516
Drug: Conventional crater
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional crater chop (CC)
Study: 34158028
Drug: mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mepolizumab 100 mg SC
Study: 35675051
Drug: 1.1% TTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% TTP formulation containing retinol, retinyl acetate, and retinyl palmitate for 24 weeks
Study: 35675051
Drug: 1.1% TTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1% TTP formulation
Study: 32971155
Drug: Optimum diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum diabetes care including Ramadan-focused education, flash glucose monitoring, dietary advice, and treatment adjustment
Study: 35380268
Drug: Anti-inflammatory dietary
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory dietary intervention (six monthly food-preparation workshops and twelve motivational interviewing telephone calls)
Study: 32673517
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abdominal compression and propranolol
Study: 35653554
Drug: Ciprofol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol (0.4 mg/kg)
Study: 33583009
Drug: Rare infectious
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rare infectious agents found in patients with IV drug abuse (Pseudomonas aeruginosa, Staphylococcus hominis, Citrobacter).
Study: 34191552
Drug: Vestibular rehabilitation
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestibular rehabilitation therapy (VRT) plus modified Epley procedure for 4 weeks
Study: 32057960
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream (1.5% twice daily)
Study: 32057960
Drug: Vehicle (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (twice daily)
Study: 32057960
Drug: Triamcinolone cream
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone cream (0.1% twice daily for 4 weeks then vehicle for 4 weeks)
Study: 35041780
Drug: Balanced multielectrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced multielectrolyte solution (BMES)
Study: 34635771
Drug: SnMP 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnMP 3.0 mg/kg
Study: 34635771
Drug: SnMP 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SnMP 4.5 mg/kg
Study: 35460295
Drug: Salbutamol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (16 mg for 4 days, then 24 mg 1½ h before exercise)
Study: 32869587
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate dispersible tablet 5 mg, orally 3 times a day for 4 weeks.
Study: 33931347
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy intervention
Study: 36282186
Drug: Alirocumab (15-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (15-100 mg)
Study: 36282186
Drug: Evolocumab (21-140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (21-140 mg)
Study: 34650017
Drug: One G
Normalized name: Arlatone G
Approvals — FDA: no, EMA: no, PMDA: no
Description: One G rotary file
Study: 36414206
Drug: digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital cognitive behavior therapy (dCBT)
Study: 32202265
Drug: CGly, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGly, 800 mg kg‐1
Study: 35183773
Drug: Atezolizumab with
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab with antibiotic use
Study: 35183773
Drug: Atezolizumab without
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab without antibiotic use
Study: 32321767
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and gemcitabine
Study: 35297493
Drug: IL-6 inhibitors
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 inhibitors (e.g., Tocilizumab)
Study: 34154931
Drug: Insulin syringe
Normalized name: Insulin Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin syringe reusage for more than five times
Study: 32109313
Drug: Ketamine in
Normalized name: ketamine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine in conjunction with morphine
Study: 32109313
Drug: Standard morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard morphine equivalent therapy alone
Study: 33399632
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 100,000 IU of vitamin D (SG)
Study: 33399632
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses of 400 IU of vitamin D (CG)
Study: 35365179
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg alemtuzumab
Study: 35365179
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg alemtuzumab
Study: 33880019
Drug: Nebulized glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized glycopyrrolate (GLY) 25 ?g twice-daily (BID)
Study: 32681596
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg·kg‐1)
Study: 34035087
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy (EULT) programme plus usual care
Study: 35545258
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (moderate intensity physical activity twice weekly at a centre and up to four times weekly at home, plus personalised nutritional counselling)
Study: 36243351
Drug: S. sonnei-rEPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. sonnei-rEPA vaccine (adults)
Study: 36243351
Drug: Control vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccines (adults)
Study: 32649352
Drug: P2Y12 inhibition
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibition and aspirin
Study: 34530881
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine administered every 18-24 hours, doses escalated daily (5-10 mg), for a minimum of 2 doses and a maximum of 5 doses (96 hours).
Study: 32702001
Drug: Antibiotic prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribed
Study: 32702001
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prescribed
Study: 32342266
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of vitamin E on staple lines and anastomoses (G1)
Study: 34475360
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg twice daily for 7 days
Study: 34475360
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and Placebo (both groups)
Study: 35229407
Drug: MM-FAT (multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-FAT (multimodal approach to food art therapy)
Study: 32319528
Drug: ZYN 3
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZYN 3 mg
Study: 32319528
Drug: ZYN 6
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZYN 6 mg
Study: 32319528
Drug: ZYN 8
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ZYN 8 mg
Study: 32319528
Drug: General 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: General 8 mg snus
Study: 32319528
Drug: Longhorn Natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longhorn Natural 18 mg moist snuff
Study: 32319528
Drug: General 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: General 2 × 8 mg snus pouches
Study: 34323443
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.4 microgram/kg bolus followed by 0.4 microgram/kg/h infusion)
Study: 32709710
Drug: Regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine)
Study: 32709710
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia (0.5% L-bupivacaine and 1% lidocaine)
Study: 35266409
Drug: Medication reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reduction (deprescribing antihypertensive medications)
Study: 35266409
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (continuation of antihypertensive medications)
Study: 33256659
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation (tDCS) with fluoxetine, 20 minutes of 2 mA stimulation, three times per week for 8 weeks.
Study: 33256659
Drug: Fluoxetine only
Normalized name: Fluoxetine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine only (sham control).
Study: 34477854
Drug: ON101 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON101 cream (n = 122)
Study: 35783542
Drug: Persian herbal
Normalized name: PERUVIAN BALSAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persian herbal medicine formula + routine treatment
Study: 32643211
Drug: Traditional Oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Oral Health Education (TOHE)
Study: 36371742
Drug: Oxycodone-acetaminophen (opioid)
Normalized name: acetaminophen / oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone-acetaminophen (opioid)
Study: 32663820
Drug: Chlorthalidone (CTD)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (CTD) 12.5 mg once daily (QD)
Study: 33665897
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to participate in randomized controlled trials of medications
Study: 32799565
Drug: Generic empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Generic empagliflozin tablet (25 mg)
Study: 32799565
Drug: Brand-named empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brand-named empagliflozin tablet (Jardiance®) (25 mg)
Study: 35773718
Drug: Mobile device-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile device-based cognitive behavior therapy (CBT)
Study: 35773718
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatments (Control group)
Study: 34232202
Drug: Magnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic field therapy (3 mT and 10 Hz) for 30 minutes daily for 11 days
Study: 34232202
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no magnetic field therapy)
Study: 32955839
Drug: Pelvic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic and core strength training (PCST) program, 8 weeks, twice/week
Study: 35657948
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot medroxyprogesterone acetate
Study: 34394913
Drug: Bufei Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bufei Huoxue (BFHX) capsules
Study: 32629035
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (90.9% acyclovir, 6.2% ganciclovir, 2.9% both)
Study: 35833805
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy (2.0 mg intravitreous)
Study: 35833805
Drug: Bevacizumab first
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab first (1.25 mg intravitreous)
Study: 34528239
Drug: eltrombopag 25
Normalized name: eltrombopag 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eltrombopag 25 mg/day for 2 weeks
Study: 34528239
Drug: eltrombopag 25
Normalized name: eltrombopag 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eltrombopag 25 mg/day
Study: 33415861
Drug: Combined acupuncture-medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acupuncture-medicine anesthesia
Study: 35954713
Drug: 1% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CHX gel
Study: 35954713
Drug: 0.12% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% CHX solution
Study: 33150743
Drug: Obesogenic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obesogenic medications
Study: 35855954
Drug: sGDNF in
Normalized name: GDNF Liatermin
DrugBank: Liatermin (DB06489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sGDNF in CHB patients with fibrosis (28.4 pg/ml)
Study: 35855954
Drug: sGDNF in
Normalized name: GDNF Liatermin
DrugBank: Liatermin (DB06489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sGDNF in CHB patients with cirrhosis (33.8 pg/ml)
Study: 32296197
Drug: Concomitant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiotherapy with temozolamide after two cycles of standard chemotherapy (Group-B)
Study: 32608151
Drug: 755 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 755 nm picosecond Alexandrite laser treatment
Study: 34032389
Drug: Comprehensive diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive diabetes treatment (inpatient treatment for 2 weeks)
Study: 32822260
Drug: Sham capsule
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham capsule
Study: 35598024
Drug: lecanemab, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: lecanemab, an anti-Aβ protofibril antibody
Study: 33514787
Drug: Fluoride-free hydroxyapatite
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-free hydroxyapatite toothpaste (used three times daily)
Study: 35848716
Drug: Treatment-as-usual (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (N = 48)
Study: 32393252
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg Q4W for 16 weeks
Study: 36105381
Drug: BUZZY device
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUZZY device with anesthetic gel
Study: 36105381
Drug: Cold alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold alone with anesthetic gel
Study: 32757065
Drug: Carbohydrate-protein solution
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-protein solution (CHO-P; 0.8 g carbohydrate kg BM-1 + 0.8 g protein kg BM-1)
Study: 32757065
Drug: Carbohydrate (CHO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO; 1.6 g per kg body mass)
Study: 32757065
Drug: Carbohydrate-protein solution
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-protein solution (CHO-P)
Study: 34473389
Drug: Self-completed survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-completed survey measuring treatment of skin cancers
Study: 34675131
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment
Study: 32116211
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of non-pharmacologic and pharmacologic therapies
Study: 34509775
Drug: Nightly medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly medication use with standard-dose zolpidem (QHS)
Study: 34509775
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing with standard-dose zolpidem and placebos (IDwP)
Study: 34509775
Drug: Continued QHS
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued QHS full dose treatment (FD/FD)
Study: 34509775
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing with standard-dose zolpidem and placebos (FD/VD)
Study: 34509775
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing with placebos (VD/VD)
Study: 32108442
Drug: Sweet breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweet breakfast (30% by weight added sugar; average 32 g of sugar)
Study: 32108442
Drug: Plain breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain breakfast (no added sugar; average 8 g of sugar)
Study: 34698782
Drug: Platelet-Rich Plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-Rich Plasma (PRP) injections (n=48)
Study: 34698782
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injections (n=52)
Study: 32827307
Drug: Prophylactic nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic nimodipine treatment (parenteral nimodipine from the day before surgery until the seventh postoperative day)
Study: 35063028
Drug: Intrabronchial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrabronchial administration of autologous adipose-derived mesenchymal stem cells (AD-MSC)
Study: 33583208
Drug: Nurse-conducted telephone
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-conducted telephone guidance for bowel preparation before colonoscopy
Study: 32469375
Drug: Mind Mapping
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mind Mapping (MM) group, instructed on how to construct mind maps and created weekly mind maps for 9 weeks.
Study: 32852619
Drug: Oxygen-enriched oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-enriched oil-based gel dressing (G1)
Study: 32852619
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid cream (G2)
Study: 33454539
Drug: Tablet-computer with
Normalized name: ephedrine Oral Tablet [Primatene with ephedrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-computer with survivor stories (3 times in 12 months)
Study: 35150025
Drug: Cumulative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative steroid dose
Study: 33620545
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ) supplementation (140 mL, 13 mmol NO3‐)
Study: 33538566
Drug: Novel topical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel topical cosmetic cream (NCC), applied twice daily.
Study: 34446544
Drug: N-acetylcysteine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (150 mg/kg)
Study: 32119035
Drug: CBD10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD10 (10 mg/kg/d)
Study: 32119035
Drug: CBD20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD20 (20 mg/kg/d)
Study: 35672606
Drug: Omega-3/6 dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3/6 dietary supplement (two capsules containing 279 mg EPA, 87 mg DHA, 30 mg GLA each)
Study: 35672606
Drug: Omega-3/6 dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3/6 dietary supplement
Study: 34352149
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Tenofovir Alafenamide (TAF)